Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus PAROMOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus PAROMOMYCIN SULFATE.
AMIKIN vs PAROMOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Paromomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria. It also has direct amebicidal activity against Entamoeba histolytica by inhibiting protein synthesis.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
25-35 mg/kg/day orally in 3 divided doses for 5-10 days for intestinal amebiasis; 1 g orally every 8 hours for 7 days for cryptosporidiosis.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Terminal elimination half-life: 2–3 hours in normal renal function; extends to 24–48 hours or longer in severe renal impairment, necessitating dose adjustment.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic